Minnesota RETAIN Phase 2 (MN RETAIN)

April 9, 2024 updated by: Laura E. Breeher, Mayo Clinic

Minnesota Retaining Employment and Talent After Injury/Illness Network (RETAIN) Phase 2

This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

3200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic Rochester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • > 18 years old
  • MN resident
  • Works in MN
  • Employed or currently in the labor force
  • Has worked at least one day within the last 3 months (80% or more of participants)
  • Has worked at least one day greater than 3 months but less than 6 months prior (up to 20% of participants)

  • Meets one of the following:

    • Diagnosis of a work related or personal injury or illness that impacts employment
    • Invasive procedure (e.g., surgery) within the past 12-weeks or anticipated within the next 8-weeks that impacts employment

Exclusion Criteria:

  • Legal representation/litigation at the time of enrollment related to the medical condition.
  • Does not have the capacity to give appropriate informed consent
  • Employed by a RETAIN healthcare recipient or subrecipient with an existing return-to-work program for employees (i.e. Mayo Clinic employees)
  • Worker's compensation recipients that have a qualified rehabilitation consultant (QRC) or a disability case manager (DCM)
  • Pending application or receiving of Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group
Individuals will receive a handout with additional job related services; e.g. Job Accommodation Network.
Experimental: Intervention Group
Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.
Other: RETAIN Program
Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Workers to maintain employment
Time Frame: 12 months
Total number of workers employed at the time of program completion and who have maintained employment 12 months after enrollment.
12 months
Reduction on work disability at 1 years
Time Frame: 1 year
Total number of enrollees that applied for SSDI or SSI during any of the 1 year after enrollment.
1 year
Reduction in long term work disability
Time Frame: 5 years
Total number of enrollees that applied for SSDI or SSI during any of the 5 year after enrollment.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Collaborators

Minnesota Department of Health
Workforce Development, Inc.
United States Social Security Administration
Minnesota Department of Employment and Economic Development
Minnesota Department of Labor and Industry
Mathematica Policy Research
United States Department of Labor

Investigators

  • Principal Investigator: Laura Breeher, MD, MPH, Mayo Clinic
  • Principal Investigator: Clayton Cowl, MD,MS, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2021

Primary Completion (Estimated)

May 1, 2025

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

January 18, 2022

First Submitted That Met QC Criteria

January 18, 2022

First Posted (Actual)

January 31, 2022

Study Record Updates

Last Update Posted (Actual)

April 11, 2024

Last Update Submitted That Met QC Criteria

April 9, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 21-006979
  • FP00100838.02 (Other Grant/Funding Number: Department of Labor and Social Security Administration)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disability

Clinical Trials on RETAIN Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe